Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 8Metastatic Castration-resistant Prostate Cancer 2Urogenital Neoplasms 1Prostatic Diseases 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Neoplasms by Site 1Neoplasms 1Male Urogenital Diseases 1Genital Neoplasms, Male 1

Interventions

Prednisone 2Pluvicto 2rucaparib 1ebastine 1copanlisib 1cabazitaxel 1afuresertib 1Docetaxel 1Clinical Trials, Phase I as Topic 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Metastatic Castration-resistant Prostate Cancer × Pluvicto × Clear all
NCT05682443 2026-05-22

PRESERVE-006

OncoC4, Inc.

Phase 1/2 Active not recruiting
148 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05340374 2025-04-06

LuCAB

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Active not recruiting
35 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡